Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 4,724,584	$ 6,168,754
Restricted cash		231,838
Accounts receivable, net	2,384,001	1,986,663
Inventories, net	2,082,340	1,414,600
Loans to customer and supplier	2,952,293	2,892,868
Other receivables	901,482	483,884
Prepayments	8,838,964	9,029,524
Other current assets	8,174	132,746
Deferred tax assets	27,598	27,042
Total current assets	21,919,436	22,367,919
Property, plant and equipment, net	5,263,250	4,813,232
Construction in progress	1,095,988	295,248
Intangible asset, net	1,187,429	1,238,025
Other non-current assets		134,736
Total assets	29,466,103	28,849,160
Current liabilities:
Accounts payable	843,161	646,649
Advance from customers	292,729	128,321
Other payables and accrued liabilities	844,365	942,793
Income tax payable	1,915,712	1,842,139
Convertible notes, net	7,509,232	7,267,677
Current portion of long-term borrowings	1,294,156	1,268,106
Total current liabilities	12,699,355	12,095,685
Advance from government grant	82,086	37,948
Long-term borrowings	808,848	792,567
Total liabilities	13,590,289	12,926,200
Commitments and contingencies
EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of June 30, 2013 and December 31, 2012	13,324	13,324
Additional paid-in capital	12,220,181	12,220,181
Retained earnings	1,927,571	2,485,736
Statutory reserve	373,406	373,406
Accumulated other comprehensive income	1,171,409	658,870
Total Tanke Biosciences Corporation stockholders' equity	15,705,891	15,751,517
Non-controlling interest	169,923	171,443
Total Equity	15,875,814	15,922,960
Total Liabilities and Equity	$ 29,466,103	$ 28,849,160